RecruitingNCT06781359

Study on Plasmablastic Lymphoma Patients

An International Multicenter Observational Retrospective Study on Plasmablastic Lymphoma Patients

Sponsor

Fondazione Italiana Linfomi - ETS

Enrollment

200 participants

Start Date

Feb 14, 2025

Study Type

OBSERVATIONAL

Conditions

Plasmablastic Lymphoma

Summary

This is an observational, multicenter, international and retrospective study, that aims to collect data on clinical and pathological characteristics, treatment regimens, outcome, and prognostic factors (clinical, biomarkers and/or radio-metabolic) in patients affected by PBL.

Eligibility

Min Age: 15 Years

Plain Language Summary

Simplified for easier understanding

This is a research study reviewing medical records of people diagnosed with plasmablastic lymphoma — a rare and aggressive type of blood cancer — between 2000 and 2022. The goal is to better understand the disease, how it was treated, and patient outcomes. **You may be eligible if...** - You were diagnosed with plasmablastic lymphoma between January 2000 and December 2022 - Your diagnosis was confirmed by tissue biopsy - You are 18 or older - Complete medical records and tissue samples are available **You may NOT be eligible if...** - Your diagnosis was a different type of lymphoma - Sufficient medical records or tissue samples are not available Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(23)

IRCCS Centro di Riferimento Oncologico di Aviano, Divisione di Oncologia e dei Tumori immuno-correlati

Aviano, PN, Italy

Ospedale C.e G. Mazzoni, U.O.C. di Ematologia

Ascoli Piceno, Italy

ASST Spedali Civili di Brescia, Ematologia

Brescia, Italy

A.O. S. Croce e Carle, S.C. di Ematologia e Trapianto di Midollo Osseo

Cuneo, Italy

Azienda Ospedaliera Universitaria Careggi, Unità funzionale di Ematologia

Florence, Italy

ASST -Fatebenefratelli - Polo Luigi Sacco Oncologia

Milan, Italy

ASST Grande Ospedale Metropolitano Niguarda, SC Ematologia

Milan, Italy

Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia

Milan, Italy

Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Ematologia

Milan, Italy

Fondazione IRCCS San Gerardo dei Tintori, Ematologia

Monza, Italy

AOU Maggiore della Caritа di Novara, SCDU Ematologia

Novara, Italy

Azienda Ospedaliera Universitaria di Padova, Ematologia

Padova, Italy

Presidio ospedaliero A. Tortora, U.O. Onco-ematologia

Pagani, Italy

Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova, Ematologia

Reggio Emilia, Italy

Azienda Ospedaliera Universitaria Sant' Andrea, Ematologia

Roma, Italy

Policlinico Umberto I - Università La Sapienza, Istituto Ematologia, Dipartimento di Medicina Traslazionale e di Precisione

Roma, Italy

Universitа Cattolica S. Cuore, Ematologia

Roma, Italy

Azienda Ospedaliero Universitaria Senese, U.O.C. Ematologia

Siena, Italy

A.O.U. Città della Salute e della Scienza di Torino, Ematologia Universitaria

Torino, Italy

A.O.U. Città della Salute e della Scienza di Torino, S.C. Ematologia

Torino, Italy

Ospedale S. Chiara, S.S. di Ematologia

Trento, Italy

ULSS2 Marca Trevigiana, Ospedale Ca' Foncello, S.C di Ematologia

Treviso, Italy

ULSS 8 Berica - Ospedale S. Bortolo, Ematologia

Vicenza, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06781359

Related Trials

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

NCT053894231 location

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

NCT0491524818 locations

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

NCT056635028 locations

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

NCT041393048 locations